Neolys Pharma has secured funding from the Programme de soutien aux organismes (PSO) of Quebec’s Ministère de l’Économie, de l’Innovation et de l’Énergie.

The funding supports preclinical work on RM-581, a synthetic aminosteroid the company is developing for cancers with poor prognosis. It helps consolidate the research and development activities carried out from Quebec City.

The PSO supports organizations that contribute to economic development and innovation in Quebec. For Neolys Pharma, it represents meaningful backing at a defining stage in the development of its drug candidate.